

The Latin American Consortium of Studies in Obesity (LASO)

L. E. Bautista¹, J. P. Casas², V. M. Herrera¹, J. J. Miranda², P. Perel², R. Pichardo³, A. González³, J. R. Sanchez⁴, C. Ferreccio⁵, X. Aguilera⁶, E. Silva⁷, M. Oróstegui⁸, L. F. Gómez⁹, J. A. Chirinos¹⁰, J. Medina-Lezama¹¹, C. M. Pérez¹², E. Suárez¹², A. P. Ortiz¹², L. Rosero¹³, N. Schapochnik¹⁴, Z. Ortiz¹⁵ and D. Ferrante¹⁶, on behalf of the investigators of the Latin-American Consortium of Studies in Obesity (LASO)

¹Department of Population Health Sciences, University of Wisconsin, Madison, WI, USA; ²Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK; ³Instituto Dominicano de Cardiología, Santo Domingo, República Dominicana; ⁴Centro Nacional de Alimentación y Nutrición, Instituto Nacional de Salud, Lima, Perú; ⁵Departamento de Salud Pública, Pontificia Universidad Católica de Chile, Santiago, Chile; ⁶Ministerio de Salud de Chile, Santiago, Chile; ⁷Instituto de Investigación y Estudios de Enfermedades Cardiovasculares, Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela; ⁸Cardiovascular Diseases Epidemiologic Observatory, Epidemiologic Research Center, Universidad Industrial de Santander, Bucaramanga, Colombia; ⁹Health Division, Fundación FES Social, Bogotá, Colombia; ¹⁰Division of Cardiology, University of Pennsylvania School of Medicine and Philadelphia VA Medical Center, Philadelphia, PA, USA; ¹¹Santa María Catholic University and Santa María Research Institute, Arequipa, Perú; ¹²Department of Biostatistics and Epidemiology, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico; ¹³Universidad de Costa Rica, Centro Centroamericano de Población, San José, Costa Rica; ¹⁴Ministerio de Salud de la Provincia de Tierra del Fuego, Ushuaia, Argentina; ¹⁵Instituto de Investigaciones Epidemiológicas Academia Nacional de Medicina, Buenos Aires, Argentina; ¹⁶Ministerio de Salud y Ambiente, Buenos Aires, Argentina

Received 8 December 2008; revised 23 February 2009; accepted 24 February 2009

Address for Correspondence: LE Bautista, Department of Population Health Sciences, University of Wisconsin-Madison, 610 Walnut Street, 703 WARF, Madison, WI 53726-2397, USA. E-mail: lebautista@wisc.edu; JP Casas, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. E-mail: Juan.Pablo-Casas@lshtm.ac.uk

Summary

Current, high-quality data are needed to evaluate the health impact of the epidemic of obesity in Latin America. The Latin American Consortium of Studies of Obesity (LASO) has been established, with the objectives of (i) Accurately estimating the prevalence of obesity and its distribution by sociodemographic characteristics; (ii) Identifying ethnic, socioeconomic and behavioural determinants of obesity; (iii) Estimating the association between various anthropometric indicators or obesity and major cardiovascular risk factors and (iv) Quantifying the validity of standard definitions of the various indexes of obesity in Latin American population. To achieve these objectives, LASO makes use of individual data from existing studies. To date, the LASO consortium includes data from 11 studies from eight countries (Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Peru, Puerto Rico and Venezuela), including a total of 32 462 subjects. This article describes the overall organization of LASO, the individual studies involved and the overall strategy for data analysis. LASO will foster the development of collaborative obesity research among Latin American investigators. More important, results from LASO will be instrumental to inform health policies aiming to curtail the epidemic of obesity in the region.

Keywords: Consortium, health surveys, Latin America, obesity, risk factors.

obesity reviews (2009) **10**, 364–370

Introduction

The parallel processes of economic growth, migration and urbanization in Latin America have shaped the epidemiological transition by increasing life expectancy and modifying lifestyles (1–3). In fact, the increase in the consumption of high-energy-density foods and the reduction in the levels of physical activity have been recognized as the main factors associated with the accelerated epidemic of obesity in the region (4,5). This epidemic is a matter of great concern because obesity constitutes a major modifiable risk factor for most of the leading causes of disability and mortality in Latin American countries, particularly cardiovascular diseases (CVD), diabetes mellitus, osteoarthritis and certain types of cancers (6,7).

Although existing evidence suggests a parallel increment in total energy and fat consumption, the prevalence of sedentary behaviours and the prevalence of obesity (8–10), there are limited reliable data on the magnitude and consequences of the epidemic of obesity in the region. Furthermore, the association of behavioural and environmental factors with obesity, as well as the relationship between obesity and other chronic diseases, might be more complex in Latin America than in more homogeneous populations. In fact, the current definition of obesity, primarily derived from White populations from Europe and the United States (6), might not be optimal to identify individuals at high risk of CVD or of diabetes mellitus (11,12).

Estimates of the prevalence of obesity have shown a great variability in Latin American populations, ranging from 9.9% to 35.7% (13). Women and individuals living in urban areas have been identified as the groups predominantly affected (14). In addition, obesity has been independently associated to low socioeconomic status and poorer educational level (15,16), and contributes to the accentuation of health inequalities in the region (17). There is also evidence of a secular trend towards the increase in levels of obesity among the most economically developed Latin American countries during the past three decades (14,18); however, similar data are not available for more disadvantaged populations. Moreover, most of the information on obesity has been obtained from nutritional surveys conducted during the first half of the nineties in adult women, mostly in urban settings, and little is known about adult men or the growing elderly population as well as rural obesity profiles.

In order to compose a comprehensive and updated picture of the impact of obesity in Latin America, we have established a multi-country consortium of obesity-related epidemiological studies conducted in the region. This initiative constitutes a strategy aimed to efficiently identify individual and population determinants of obesity, as well as to assess the role of obesity on the burden of CVD. We have chosen to focus on CVD for several reasons. First,

CVD is the leading cause of non-traumatic mortality in Latin America (3,7); second, the projected burden of CVD will double during the following 20 years in the region (19,20); and third, there is a well-established association between obesity and the incidence of major cardiovascular risk factors and clinical cardiovascular events (21).

The specific objectives of the Latin American Consortium of Studies in Obesity (LASO) are (i) To accurately estimate the prevalence of obesity and its distribution by sociodemographic characteristics in Latin America; (ii) To identify ethnic, socioeconomic and behavioural factors (nutritional and physical activity patterns) associated to the prevalence of obesity; (iii) To estimate the association between various anthropometric indicators of obesity and classic cardiovascular risk factors and (iv) To quantify the validity of standard definitions of obesity in this population. Along with the accomplishment of these objectives, it is expected that the consolidation of LASO will foster the development of collaborative, harmonized studies on the association between obesity and other relevant chronic diseases in the region. LASO will help understand the obesity epidemic and develop future studies to evaluate the determinants and the impact of obesity in Latin America.

The aim of this manuscript is to present the protocol for LASO, describe the use of standardized methodologies for the pooling of data from individual studies and provide a general description of participating studies and their methodologies.

Materials and methodology

Identification and selection of studies

Studies included in LASO are cross-sectional or prospective population-based cohort studies, based on random samples of well defined free-living population. All studies have individual data on demographic and socioeconomic indicators and anthropometric indicators of obesity collected through physical examination. Moreover, they have at least one of the following (i) Direct measurement of major cardiovascular risk factors; (ii) Determination of levels of physical activity and (iii) Determination of nutritional patterns. The search for potential participant studies is based on computer-assisted literature searches of health-related databases; hand-searching of obesity, cardiology, epidemiology and other relevant journals; and personal communications with cardiovascular and obesity researchers from the region.

Ethical approval, informed consent and confidentiality of the data

All studies have been approved by their respective local Institutional Review Board, and all participants provided

their informed consent. The investigators of the original studies provide written consent for the use of their data before transferring and inclusion into the Consortium's central database at the University of Wisconsin at Madison. The data remain the property of the principal investigators of each participant study and are securely stored in study-dedicated computers. The central database does not include codes or data that may directly or indirectly allow the identification of individuals participating in the original studies.

Consortium management and coordination

The LASO Steering Committee includes the principal investigators from all original studies. The tasks of this committee include (i) Coordinating the recruitment of new studies; (ii) Developing and prioritizing research questions to be addressed by the analysis of pooled data; (iii) Identifying and securing funds for the study; (iv) Producing and disseminating scientific reports of the ongoing research projects among members of the Consortium and (v) Acting as a publication committee. Parallel to the Steering Committee, a statistical centre has been constituted as an external academic instance responsible for the creation and management of the Consortium's central database, as well as for data analysis and generation of preliminary reports. This centre is based at the Department of Population Health Sciences, University of Wisconsin at Madison.

Study variables

Individual data collected in each study are categorized in five domains (Table 1) (i) Demographics, including age, gender, race or ethnic group; (ii) Indicators of socioeconomic status, including socioeconomic stratification, educational attainment, income, occupation and area of residency; (iii) Anthropometric indicators of total and regional obesity, measured by physical examination; (iv) Classic cardiovascular risk factors, including measurements of blood pressure and the laboratory assessment of glucose and lipid fractions and (v) Behavioural risk factors, including smoking status, alcohol consumption, physical activity and nutritional intake. Continuous variables such as anthropometric measures, blood pressure, glucose and lipid fractions are categorized according to current standard definitions. Whenever possible, categorical variables are recoded following standard procedures to maximize comparability among studies. Data on study-specific procedures are used to assess heterogeneity among studies.

Data transfer and checking

Password-protected data files are transferred from the individual studies to the Consortium's statistical centre using

Table 1 Variables available in the Latin American Consortium of Studies in Obesity (LASO)

Domain	Variable (description)
Demographic	Age (years); gender (male/female) Ethnicity (Amerindian/Black/White/other)
Socioeconomic	Educational attainment (highest level or total years) Income (individual or household) Occupation (occupational categories) Area of residency (urban/rural)
Anthropometry*	Body weight (kg)/height (m) Waist circumference (cm) Hip circumference (cm)
Cardiovascular and metabolic risk factors*	Systolic/diastolic blood pressure (mmHg) Glucose (mmol L ⁻¹) Total, HDL and LDL cholesterol (mmol L ⁻¹) Triglycerides (mmol L ⁻¹)
Behavioural risk factors	Smoking status (never, past or current; cigarettes per day) Alcohol consumption (type of beverage, frequency and quantity) Physical activity (type of activity, frequency and duration) Foods/nutrients' intake (food frequency questionnaires)

*Measured by physical examination or laboratory analysis.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.

electronic mailing. A codebook and a transference form containing a list of parameters directly estimated from the original datasets are included as part of the data transfer protocol. For security purposes, the datasets and accompanying files are encrypted before transferring using keywords known only to the coordinator of the Consortium and the principal investigators of each study. Specific parameters calculated from each study after data transfer are compared with those obtained by the study investigators before data transfer. In the case of inconsistencies, the data are back-transferred to ensure identical results are obtained with both datasets. The data are then converted to a standard format and incorporated to the Consortium's central database.

Statistical analysis

Specific data analysis strategies are used for each specific study using LASO data. However, some statistical procedures are applied for all analyses. We use multivariate imputation by chained equations to fill out missing values within studies in order to minimize selection bias because of missing data (22). Multiple imputed datasets are generated and the parameters of interest are averaged across datasets, using Rubin's formula (23). In addition, we use post-stratification by the age and gender distribution of the

whole population in the countries included in the specific analysis as a way to minimize bias resulting from non-response and sampling frame under-coverage (24). Post-strata are constructed using the population totals by country, gender and age group (20–29, 30–39, 40–49, 50–59, 60–69, 70–79 and 80 years and older). Population distribution data are obtained from the U.S. Census Bureau (<http://www.census.gov>) for Puerto Rico and from the Centro Latinoamericano y Caribeño de Demografía – CELADE (<http://www.cepal.org.ar/Celade>) for all other countries.

Multiple weighted linear and logistic regression are implemented in order to (i) Compare the distribution of anthropometric indicators and the prevalence of obesity and cardiovascular risk factors in groups defined by demographic and socioeconomic characteristics; (ii) Predict the prevalence of total and regional obesity in these groups and (iii) Quantify the independent effect of total and regional obesity on the distribution of individual cardiovascular risk factors and coronary heart disease risk. In order to determine which anthropometric indicator of obesity better identifies individuals with specific cardiovascular risk factors or who are at high risk of coronary heart disease, we estimate and compare the areas under the receiver operator characteristic (ROC) curves using the method of placement values (25,26). Finally, optimal cut-points for the anthropometric indicators of obesity are also determined on the basis of the ROC analysis by estimating the values of the indicator that minimize the cost of misclassifying individuals according to the presence of specific cardiovascular risk factors or the risk of coronary heart disease (27).

Publication policy

Manuscripts derived from the analysis of aggregated data undergo an internal peer-review process. Manuscripts cir-

culate among the members of the Steering Committee, who provide comments and generate a feedback report to the main authors. The main author addresses and responds to the comments and prepares a final revised version. LASO's Steering Committee approves the final manuscript before submission. Finally, as part of a strategy of communication and recruitment, the Consortium has developed a website (<http://www.pophealth.wisc.edu/laso>), which contains general information on the participant studies, the principal investigators and their groups, and links to the all the publications derived from the analysis of pooled data.

Results

Eleven studies (28–38) from eight countries in Latin America and the Caribbean (Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Peru, Puerto Rico and Venezuela) are currently included in the LASO, including a total of 32 462 subjects (Table 2). The overall mean age is 45.8 years (standard deviation 18.6 years; range: 15–109 years) and the male proportion is 40.6%, ranging from 31.0% to 50%. Four studies are national health surveys (29,32–34), but one of them is restricted to urban population (33). In addition, one study was conducted at the state level (38), five exclusively targeted urban populations from single cities (28,30,31,36,37) and other sampled an urban and a rural population (35).

Data on demographic and socioeconomic characteristics, smoking, medical history and current treatment of hypertension and diabetes were collected by trained interviewers using similar questionnaires (available to the members of the statistical centre) in all studies. Standing height and weight were measured in all surveys with the participants wearing light clothing and no shoes. Waist circumference was measured at the umbilical level in five studies (28,31,32,36,38), at the midpoint between the lowest rib and the iliac crest in four studies (29,30,34,35), at the high

Table 2 Characteristics of the studies from the Latin American Consortium of Studies in Obesity (LASO)

Study	Location	Year	Target	Sample	Age	Male
Encuesta de Factores de Riesgo (28)	Argentina, Ushuaia/Rio Grande	2003–2004	City	1135	18–65	48%
Encuesta Nacional de Salud (29)	Chile	2003	National	3619	16–97	45%
CARMEN (30)	Colombia, Bogotá	2001	City	2962	15–69	43%
CARMEN (31)	Colombia, Bucaramanga	2001	City	2994	15–66	36%
CRELES (32)	Costa Rica	2004–2006	National	2826	60–109	46%
EFRICARD (33)	Dominican Republic	1998	National (urban)	6184	18–75	34%
ENINBSC-ECNT (34)	Peru	2005	National	4209	20–95	50%
PERU MIGRANT (35)	Peru, Lima/Ayacucho	2007–2008	Urban/rural	990	29–92	47%
PREVENCION (36)	Peru, Arequipa	2004–2006	City	1878	20–80	46%
Metabolic syndrome in San Juan (37)	Puerto Rico	2005–2007	City	865	21–79	35%
The Zulia CHD Factor Study (38)	Venezuela, Zulia	1999–2001	State	4800	20–97	31%

CHD, coronary heart disease.

point of the iliac crest in one study (37), and was not measured in one study (33). Hip circumference was measured at the maximum extension of the buttocks. Blood pressure measurements were conducted at least twice in all but one study (34), following standard recommendations (39). Blood samples were obtained in all studies after ≥ 8 h of fast. Blood glucose, total cholesterol and high-density lipoprotein cholesterol were measured enzymatically by automated methods. Low-density lipoprotein (LDL) cholesterol was directly measured in two studies (36,38) and was calculated using the Friedewald equation (40) otherwise.

For effects of statistical analyses, hypertension is defined as a systolic blood pressure ≥ 140 mmHg, or as a diastolic blood pressure ≥ 90 mm Hg, or as current anti-hypertensive treatment, and participants are considered diabetics if their fasting glucose is ≥ 7.0 mmol L⁻¹ (126 mg dL⁻¹) or if they report current pharmacological treatment for diabetes (either insulin or oral agents). High total cholesterol is defined as a total cholesterol ≥ 6.15 mmol L⁻¹ (240 mg dL⁻¹). High LDL cholesterol and low high-density lipoprotein cholesterol are deemed present if the corresponding cholesterol levels are ≥ 4.10 (160 mg dL⁻¹) and < 1.03 mmol L⁻¹ (< 40 mg dL⁻¹), respectively. Hypertriglyceridemia is defined as a level of triglycerides ≥ 2.25 mmol L⁻¹ (200 mg dL⁻¹). Also, participants are classified as current smokers if they report to have smoked at least 100 cigarettes in their lives and have smoked during the previous 1–6 months in two studies (30,35) or if they were smoking at least one cigarette per day at the moment of the evaluation in the remaining studies. Overall obesity is defined as body mass index ≥ 30 kg m⁻² and abdominal obesity as a waist circumference ≥ 88 cm in women and ≥ 102 cm in men, following the recommendations of the World Health Organization (6).

Finally, as a strategy to summarize the cardiovascular risk, the expected 10-year risk of coronary heart disease is estimated in men and women 30–74 years old by using the Framingham equation (41). Considering that the equation may overestimate the absolute risk of coronary heart disease (CHD) in Latin Americans (42), we use the population-specific mean values for the risk factors in order to minimize such effect. Participants with an estimated 10-year risk of CHD $\geq 20\%$ are considered at ‘high risk’, because current standards of care recommend aggressive risk reduction and selective use of proven drug therapies in these individuals (43,44).

Conclusion

The LASO constitutes a multinational initiative to efficiently assess the public health problem of obesity, its socio-demographic and behavioural determinants, and its impact

on the risk of CVD in the region. The strategy of combining data captured at individual level from population-based studies will allow not only to increase precision in estimating the prevalence of obesity, but also to capture the heterogeneity of the effect of this condition on the health of the Latin American population. Finally, the Consortium, which currently includes data from 11 studies involving approximately 33 000 participants, will serve as framework for the interchange of observational data, discussion and interpretation of regional epidemiological evidence, and ultimately the formulation of high-quality, standardized, collaborative proposals on obesity and other prevalent chronic diseases.

Conflict of Interest Statement

None.

Acknowledgements

The authors want to express their thanks to Dr Paula Margozzini (Pontificia Universidad Católica de Chile, Chile), Claudia González (Ministerio de Salud, Chile), Dr Luis A. Santa María (Instituto Nacional de Salud, Perú), Dr Manuel Guzmán and Dr Lillian Haddock (University of Puerto Rico, School of Medicine, Puerto Rico), and Professors José Villasmil and Mairelis Nuvárez (Universidad del Zulia).

The ‘Prueba de Validación de la Encuesta Nacional de Factores de Riesgo’ was funded by the Ministerio de Salud de la República Argentina and the Gobierno de la Provincia de Tierra del Fuego, Antártida e Islas del Atlántico Sur, Argentina. The ‘Encuesta Nacional de Factores de Riesgo’ was funded by the Ministerio de Salud de la República Argentina. The ‘Encuesta Nacional de Salud 2003’ was funded by the Ministerio de Salud, Chile. The ‘Estudio CARMEN Santa Fe’ was funded by the Secretaría Distrital de Salud de Bogotá, Colombia. CARMEN-Bucaramanga was funded by the Secretaría de Salud Municipal de Bucaramanga and the Secretaría Departamental de Salud de Santander, Colombia. The ‘Costa Rica: Estudio de Longevidad y Envejecimiento Saludable (CRELES)’ was funded by The Wellcome Trust Foundation, grant number 072406. The ‘Estudio de Factores de Riesgo Cardiovascular en la República Dominicana (EFRICARD)’ was funded by the Sociedad Dominicana de Cardiología, Bristol Myers Squibb, Warners Lambert (Pfizer), Novartis, Merck Sharp Dohme and Magnachen International. The ‘Encuesta Nacional de Indicadores Nutricionales, Bioquímicos, Socioeconómicos y Culturales Relacionados con las Enfermedades Crónicas Degenerativas (ENINBSC-ECNT)’ was funded by the Instituto Nacional de Salud, Lima, Perú. JJM and the ‘PERU MIGRANT study’ were supported by a Wellcome Trust Research Training Fellowship (GR074833MA). The study ‘Prevalencia de Enfermedades

Cardiovasculares y Factores de Riesgo Coronario en Arequipa (PREVENCION)' was partially supported by the Instituto de Investigación Santa María. The study of the 'Prevalence of Metabolic Syndrome and its Individual Components in the adult population of the San Juan Metropolitan Area in Puerto Rico' was funded by an unrestricted grant from Merck Sharp & Dohme Corporation with additional support from the National Institutes of Health/National Center for Research Resources (NCRR/NIH) grant awards G12RR03051 and P20RR011126. The Zulia Coronary Heart Disease Risk Factor Study was funded by the Fondo Nacional de Ciencia, Tecnología e Innovación (FONACIT) and the Fundación Venezolana de Hipertensión Arterial (FUNDAHIPERTENSION).

References

1. Uauy R, Monteiro CA. The challenge of improving food and nutrition in Latin America. *Food Nutr Bull* 2004; **25**: 175–182.
2. Pratt M, Jacoby ER, Neiman A. Promoting physical activity in the Americas. *Food Nutr Bull* 2004; **25**: 183–193.
3. Perel P, Casas JP, Ortiz Z, Miranda JJ. Noncommunicable diseases and injuries in Latin America and the Caribbean: time for action. *PLoS Med* 2006; **3**: e344.
4. Pena M, Bacallao J. Obesity and its patterns in the region. *Rev Panam Salud Publica* 2001; **10**: 75–78.
5. Popkin BM. The shift in stages of the nutrition transition in the developing world differs from past experiences! *Public Health Nutr* 2002; **5**: 205–214.
6. World Health Organization. *Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity*. WHO: Geneva, 1997.
7. World Health Organization. *The World Health Report, 2002: Reducing Risks, Promoting Healthy Life*. WHO: Geneva, 2002.
8. Rivera JA, Barquera S, Campirano F, Campos I, Safdie M, Tovar V. Epidemiological and nutritional transition in Mexico: rapid increase of non-communicable chronic diseases and obesity. *Public Health Nutr* 2002; **5**: 113–122.
9. Albala C, Vio F, Kain J, Uauy R. Nutrition transition in Chile: determinants and consequences. *Public Health Nutr* 2002; **5**: 123–128.
10. Kain J, Vio F, Albala C. Obesity trends and determinant factors in Latin America. *Cad Saude Publica* 2003; **19**(Suppl. 1): S77–S86.
11. Sanchez-Castillo CP, Velazquez-Monroy O, Berber A, Lara-Esqueda A, Tapia-Conyer R, James WP, Encuesta Nacional de Salud (ENSA) 2002 Working Group. Anthropometric cutoff points for predicting chronic diseases in the Mexican National Health Survey 2000. *Obes Res* 2003; **11**: 442–451.
12. Pitanga FJ, Lessa I. Waist-to-height ratio as a coronary risk predictor among adults. *Rev Assoc Med Bras* 2006; **52**: 157–161.
13. Filozof C, Gonzalez C, Sereday M, Mazza C, Braguinsky J. Obesity prevalence and trends in Latin-American countries. *Obes Rev* 2001; **2**: 99–106.
14. Monteiro CA, D'A Benicio MH, Conde WL, Popkin BM. Shifting obesity trends in Brazil. *Eur J Clin Nutr* 2000; **54**: 342–346.
15. Martorell R, Khan LK, Hughes ML, Grummer-Strawn LM. Obesity in Latin American women and children. *J Nutr* 1998; **128**: 1464–1473.
16. Monteiro CA, Moura EC, Conde WL, Popkin BM. Socioeconomic status and obesity in adult populations of developing countries: a review. *Bull World Health Organ* 2004; **82**: 940–946.
17. Monteiro CA, Conde WL, Lu B, Popkin BM. Obesity and inequities in health in the developing world. *Int J Obes Relat Metab Disord* 2004; **28**: 1181–1186.
18. Williams K, Stern MP, Gonzalez-Villalpando C. Secular trends in obesity in Mexico City and in San Antonio. *Nutr Rev* 2004; **62**: S158–S162.
19. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation* 2001; **104**: 2746–2753.
20. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S, Yusuf S, INTERHEART Investigators in Latin America. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American Study. *Circulation* 2007; **115**: 1067–1074.
21. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. *Arch Intern Med* 2002; **162**: 1867–1872.
22. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. *Stat Med* 1999; **18**: 681–694.
23. Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. John Wiley & Sons: New York, 1987.
24. Korn EL, Graubard BI. *Analysis of Health Surveys*. John Wiley & Sons: New York, 1999.
25. Pepe MS, Cai T. The analysis of placement values for evaluating discriminatory measures. *Biometrics* 2004; **60**: 528–535.
26. Dodd LE, Pepe MS. Partial AUC estimation and regression. *Biometrics* 2003; **59**: 614–623.
27. Greiner M, Pfeiffer D, Smith RD. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. *Prev Vet Med* 2000; **45**: 23–41.
28. CEDES-Programa VIGI+A-Banco Mundial. In: *Encuesta de Factores de Riesgo: Adaptación y Validación del Cuestionario Propuesto por OPS Para la Vigilancia Epidemiológica de los Factores de Riesgo*. CEDES: Argentina, 2004, pp. 2003–2004.
29. Ministerio de Salud de Chile PUCdC. *Encuesta Nacional de Salud Chile 2003*. Ministerio de Salud: Santiago, Chile, 2003.
30. Gómez LF, Samper B, Espinosa G, Mateus JG, Gómez LC. Factores de riesgo cardiovascular en la localidad de Santa Fe de la ciudad de Bogotá. Resultados obtenidos en el área demostrativa Carmen. *Boletín Epidemiológico Distrital* 2004; **9**: 4–12.
31. Bautista LE, Orostegui M, Vera LM, Prada GE, Orozco LC, Herran OF. Prevalence and impact of cardiovascular risk factors in Bucaramanga, Colombia: results from the Countrywide Integrated Noncommunicable Disease Intervention Programme (CINDI/CARMEN) baseline survey. *Eur J Cardiovasc Prev Rehabil* 2006; **13**: 769–775.
32. Méndez E, Rosero-Bixby L, Fernández X, Barrantes K. Comparación de los resultados de pruebas de laboratorio seleccionadas de un estudio poblacional de adultos mayores de Costa Rica. *Población y Salud en Mesoamérica* [serial online] 2007; **5**: 2–15.
33. Pichardo R. Estudio de factores de riesgo cardiovascular en la República Dominicana (EFRICARD) 1996–1998. *Archivos Dominicanos de Cardiología* 1998; **2**: 3.
34. Ministerio de Salud. Encuesta Nacional de Indicadores Nutricionales, Bioquímicos, Socioeconómicos y Culturales relacionados con las Enfermedades Crónicas Degenerativas. Perú: 2006 (Unpublished report).
35. Miranda JJ. *The Effect on Cardiovascular Risk Factors of Migration from Rural to Urban Areas in Peru – Study Protocol*.

[MSc Epidemiology]. London School of Hygiene and Tropical Medicine, University of London: London, 2005.

36. Medina-Lezama J, Zea-Diaz H, Morey-Vargas OL, Bolanos-Salazar JF, Munoz-Atahualpa E, Postigo-MacDowall M, Corrales-Medina F, Valdivia-Ascuna Z, Cuba-Bustinza C, Paredes-Diaz S, Villalobos-Tapia P, Chirinos-Pacheco J, Goldberg RB, Chirinos JA. Prevalence of the metabolic syndrome in Peruvian Andean Hispanics: the PREVENCIÓN Study. *Diabetes Res Clin Pract* 2007; **78**: 270–281.
37. Perez CM, Guzman M, Ortiz AP, Estrella M, Valle Y, Perez N, Haddock L, Suárez E. Prevalence of metabolic syndrome in San Juan, Puerto Rico. *Ethn Dis* 2008; **18**: 434–441.
38. Florez H, Silva E, Fernandez V, Ryder E, Sulbaran T, Campos G, Calmon G, Clavel E, Castillo-Florez S, Goldberg R. Prevalence and risk factors associated with the metabolic syndrome and dyslipidemia in White, Black, Amerindian and mixed Hispanics in Zulia State, Venezuela. *Diabetes Res Clin Pract* 2005; **69**: 63–77.
39. Frohlich ED, Grim C, Labarthe DR, Maxwell MH, Perloff D, Weidman WH. Recommendations for human blood pressure determination by sphygmomanometers: report of a special task force appointed by the steering committee, American Heart Association. *Hypertension* 1988; **11**: 209A–222A.
40. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; **18**: 499–502.
41. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998; **97**: 1837–1847.
42. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P, CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. [see comment]. *JAMA* 2001; **286**: 180–187.
43. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other societies on coronary prevention. *Atherosclerosis* 1998; **140**: 199–270.
44. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. *Circulation* 2002; **106**: 3143–3421.

Copyright of Obesity Reviews is the property of Blackwell Publishing Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.